TY - JOUR
T1 - R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma
AU - Messmer, Marcus
AU - Tsai, Hua Ling
AU - Varadhan, Ravi
AU - Swinnen, Lode J.
AU - Jones, Richard J.
AU - Ambinder, Richard F.
AU - Shanbhag, Satish P.
AU - Borowitz, Michael J.
AU - Wagner-Johnston, Nina
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/4/16
Y1 - 2019/4/16
N2 - Prior to the introduction of rituximab, primary mediastinal B-cell lymphoma (PMBCL) had high rates of treatment failure with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), prompting the use of consolidative mediastinal radiation or more intensive chemotherapy regimens. Cure rates improved dramatically with rituximab, but mediastinal radiation was still commonly employed with R-CHOP. We performed a retrospective review of patients treated with R-CHOP alone without radiation for PMBCL. Of 43 patients with PMBCL, 16 received R-CHOP alone. High-risk factors included 56% with bulky disease, 75% with elevated LDH, 25% with SVC syndrome, and 13% with stage IV disease. Three-year progression-free survival (PFS) and overall survival (OS) were 93% and 100% respectively. These results suggest that R-CHOP alone has a high cure rate in PMBCL while avoiding the side effects of mediastinal radiation.
AB - Prior to the introduction of rituximab, primary mediastinal B-cell lymphoma (PMBCL) had high rates of treatment failure with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), prompting the use of consolidative mediastinal radiation or more intensive chemotherapy regimens. Cure rates improved dramatically with rituximab, but mediastinal radiation was still commonly employed with R-CHOP. We performed a retrospective review of patients treated with R-CHOP alone without radiation for PMBCL. Of 43 patients with PMBCL, 16 received R-CHOP alone. High-risk factors included 56% with bulky disease, 75% with elevated LDH, 25% with SVC syndrome, and 13% with stage IV disease. Three-year progression-free survival (PFS) and overall survival (OS) were 93% and 100% respectively. These results suggest that R-CHOP alone has a high cure rate in PMBCL while avoiding the side effects of mediastinal radiation.
KW - DLBCL
KW - PMBCL
KW - Primary mediastinal B-cell lymphoma
KW - R-CHOP
KW - diffuse large B-cell lymphoma
KW - non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85060222771&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000465176200021&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1080/10428194.2018.1519812
DO - 10.1080/10428194.2018.1519812
M3 - Article
C2 - 30656983
SN - 1042-8194
VL - 60
SP - 1261
EP - 1265
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -